NIBEC Co. Ltd (138610) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of NIBEC Co. Ltd stock KRW 8,984, price KRW 12,510, that is 28.2% below the price, quality 59 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 11,970 KRW – 55,200 KRW · fair‑value band 5,449 KRW – 11,230 KRW · the 12,510 KRW price screens above the 8,984 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow NIBEC Co. in your weekly email
Every Wednesday you see whether NIBEC Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NIBEC Co., Ltd., a healthcare company, engages in the manufacture and sale of dental bone grafts and tissue regenerative collagen products in South Korea and internationally.
Show moreShow less
It offers dental ointment, peptide containing dental bone graft materials, regenerative biomaterials, tooth whitening, tooth desensitizer, herbal toothpaste, and cosmetic products. The company was founded in 2000 and is based in Jincheon-eup, South Korea.
Stock analysis
NIBEC Co. Ltd (138610) currently trades at 12,510 KRW, while our model-based Fair Value estimate is 8,984 KRW, 28% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 16,968 KRW per share, and 6 of the 23 models we run sit above the 12,510 KRW price.
Bear case: the Asset-Based group reads lowest at 1,776 KRW, and 17 of the 23 models stay below the price. Data coverage for this calculation is low.
Scenario range: 5,449 KRW (bear) to 11,230 KRW (bull), the price of 12,510 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
NIBEC Co. Ltd reported revenue of 32.7B KRW in FY2025 versus 13.6B KRW in FY2021, a compound +24.5%/yr. Reported net income was 4.6B KRW in FY2025.
Key figures
Market cap 144B KRW (≈ $106M) Micro · P/S ratio 7.40 · EPS (TTM) −1.99 KRW · Net margin −0.1% · Return on equity −0.1% · Return on assets (EBIT) −2.5% (5-year average) · Operating margin 1.7% · Revenue (TTM) 22.6B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 76% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −28%, 138610 screens richer than that median.
Fair Value models
Bear5,449 KRWFair Value 8,984 KRWBull11,230 KRW
Price 12,510 KRW · Downside -28.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+33.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.8%
Start year 2020 (pandemic). Over 10 years: +22.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−77.4% (2020) → 15.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+67.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +63.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Top 25%
Fair Value upside−28.2% · Above median
Profitability
Return on assets7.4% · Top 25%
Net margin (12 months)−0.1% · Below median
Operating margin (12 months)1.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)−61.6% · Bottom 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is NIBEC Co. Ltd (138610) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 8,984 KRW versus a price of 12,510 KRW, about 28% lower (overvalued).
What is the fair value of 138610?
Our model-based fair value for NIBEC Co. Ltd is 8,984 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 12,510 KRW.
What is the quality score of 138610?
NIBEC Co. Ltd has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NIBEC Co. Ltd (138610)?
Our model-based price target is the fair value of 8,984 KRW (as of Nov 8, 2026) from 23 valuation models. Cautious scenario 5,449 KRW, optimistic scenario 11,230 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the NIBEC Co. Ltd stock forecast for 2026?
Our models put fair value at 8,984 KRW, about 28% lower versus a price of 12,510 KRW (overvalued). Cautious scenario 5,449 KRW, optimistic scenario 11,230 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of NIBEC Co. Ltd (138610)?
NIBEC Co. Ltd reported trailing-twelve-month revenue of about 22.6B KRW (latest available figure, as of Nov 8, 2026).
What growth is priced into NIBEC Co. Ltd (138610)?
For today's price to be fair in a discounted-cash-flow model, NIBEC Co. Ltd would have to grow free cash flow by +67.3 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +38.8 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 138610 use?
Our models discount NIBEC Co. Ltd at 11.9 %: a base by market capitalisation (micro), damped by beta 0.62, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NIBEC Co. Ltd that is +67.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has NIBEC Co. Ltd (138610) delivered so far?
Over the past 5 years revenue at NIBEC Co. Ltd grew +38.8 % a year. The price currently implies free-cash-flow growth of +67.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of NIBEC Co. Ltd (138610) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into NIBEC Co. Ltd (+67.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of NIBEC Co. Ltd (138610)?
The free-cash-flow yield on the price is 0.39 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow NIBEC Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of NIBEC Co. Ltd (138610)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NIBEC Co. Ltd it is 8,984 KRW per share (as of Nov 8, 2026), against a price of 12,510 KRW. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is NIBEC Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 138610 trades above its calculated fair value: price 12,510 KRW, fair value 8,984 KRW, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 138610?
No. The price is what the market pays today (12,510 KRW); the fair value is what the company's own numbers justify (8,984 KRW). For NIBEC Co. Ltd the two are 3,526 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is NIBEC Co. Ltd worth?
The market values NIBEC Co. Ltd at about 144B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 12,510 KRW; our models calculate a fair value of 8,984 KRW per share.
What do the bullish and bearish scenarios say about 138610?
Our models span a range for NIBEC Co. Ltd: cautious scenario 5,449 KRW, base 8,984 KRW, optimistic 11,230 KRW per share (as of Nov 8, 2026, price 12,510 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NIBEC Co. Ltd (138610)?
Balance-sheet figures for NIBEC Co. Ltd (as of Nov 8, 2026): return on equity −0.1%, debt of 0.02 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 138610 from its 52-week high?
NIBEC Co. Ltd trades at 12,510 KRW, about 76% below its 52-week high of 52,300 KRW and 3% above the low of 12,200 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 8,984 KRW is for.
Which stocks are comparable to NIBEC Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NIBEC Co. Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 12,510 KRW, calculated fair value 8,984 KRW (−28%), Quality Score 59/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 138610 calculated?
We run NIBEC Co. Ltd through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 8,984 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. NIBEC Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NIBEC Co. Ltd (138610)?
The closing price on Nov 6, 2026 was 12,510 KRW. Our model-based fair value is 8,984 KRW, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NIBEC Co. Ltd right now?
The price sits above even our optimistic bull case (11,230 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (5,449 KRW to 11,230 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of NIBEC Co. Ltd
How large is the market capitalisation of NIBEC Co. Ltd (138610)?
The market capitalisation of NIBEC Co. Ltd is 144B KRW (≈ $106M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NIBEC Co. Ltd (138610)?
The price-to-sales ratio of NIBEC Co. Ltd is 7.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NIBEC Co. Ltd (138610)?
Earnings per share at NIBEC Co. Ltd are −1.99 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of NIBEC Co. Ltd (138610)?
The net margin of NIBEC Co. Ltd is −0.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NIBEC Co. Ltd (138610)?
The return on equity (ROE) of NIBEC Co. Ltd is −0.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NIBEC Co. Ltd (138610)?
On an EBIT basis the return on assets of NIBEC Co. Ltd is −2.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NIBEC Co. Ltd (138610)?
The operating margin of NIBEC Co. Ltd is 1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NIBEC Co. Ltd (138610)?
Revenue at NIBEC Co. Ltd is growing −61.6% versus a year earlier (3y avg +14.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does NIBEC Co. Ltd (138610) carry?
The net debt of NIBEC Co. Ltd is 135M KRW (fiscal year 2023, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch NIBEC Co. Ltd in the live analysis
One click puts NIBEC Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026